|4th January 2021||Jonathan Young||2,960||Open or private sale||$25.27||$74,799.20|
|4th January 2021||Jonathan Young||100||Open or private sale||$26.00||$2,600.00|
|28th December 2020||Andrew Cheng||7,480||Exercise of derivative||$0.62||$4,637.60|
|21st December 2020||Andrew Cheng||10,500||Exercise of derivative||$0.62||$6,510.00|
|15th December 2020||Andrew Cheng||2,500||Bona fide gift||$0.00|
|11th December 2020||Andrew Cheng||50||Bona fide gift||$0.00|
|24th November 2020||Tree Partners Iv, L.P. Apple||375,000||Open or private purchase||$39.00||$14,625,000.00|
|24th November 2020||Seth Loring Harrison||375,000||Open or private purchase||$39.00||$14,625,000.00|
|23rd November 2020||G. Walmsley Graham||1,183,114||Conversion of derivative||$0.00|
|23rd November 2020||G. Walmsley Graham||1,400,761||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.